41 research outputs found
Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients.
Background: Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications.
However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being
dependent on vitamin K. The present study focused on the inactive form of MGP (dephosphorylated and
uncarboxylated: dp-ucMGP) in a population of hemodialyzed (HD) patients. Results found in subjects being treated
or not with vitamin K antagonist (VKA) were compared and the relationship between dp-ucMGP levels and the
vascular calcification score were assessed.
Methods: One hundred sixty prevalent HD patients were enrolled into this observational cohort study, including
23 who were receiving VKA treatment. The calcification score was determined (using the Kauppila method) and
dp-ucMGP levels were measured using the automated iSYS method.
Results: dp-ucMGP levels were much higher in patients being treated with VKA and little overlap was found with
those not being treated (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001). In multivariate analysis,
treatment with VKA was the most important variable explaining variation in dp-ucMGP levels even when adjusting
for all other significant variables. In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated
both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and
FGF-23, and the vascular calcification score.
Conclusion: We confirmed that the concentration of dp-ucMGP was higher in HD patients being treated with VKA. We
observed a significant correlation between dp-ucMGP concentration and the calcification score. Our data support the
theoretical role of MGP in the development of vascular calcifications. We confirmed the potential role of the inactive
form of MGP in assessing the vitamin K status of the HD patients
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
peer reviewedBACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT(50))) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806-906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT(50)) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59-1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality